Proton Pump Inhibitors with Anticoagulants

Recommendations for PPI Use

The European Society of Cardiology recommends that a proton pump inhibitor (PPI) should be considered when taking anticoagulants (like Eliquis) based on individual gastrointestinal bleeding risk factors 1
The American Gastroenterological Association suggests that risk assessment should be performed before starting a PPI in patients on anticoagulants, considering factors such as history of upper GI bleeding, advanced age, and concurrent use of multiple antithrombotic agents 2
The European Heart Journal recommends that PPIs should be considered with single anticoagulant therapy (like Eliquis alone) based on individual patient GI bleeding risk, particularly in patients with high-risk factors such as prior GI bleeding, age >60 years, or concomitant use of NSAIDs or steroids 1
The American Heart Association suggests that patients taking Eliquis with any high-risk factors, including history of upper GI bleeding, advanced age, concurrent use of multiple antithrombotic agents, or concomitant use of NSAIDs or steroids, should receive a PPI 2, 3

Clinical Decision Algorithm

The European Society of Cardiology recommends assessing bleeding risk factors, including prior GI bleeding history, age >60 years, and taking other medications that increase bleeding risk, to determine the need for PPI therapy in patients taking anticoagulants like Eliquis 1, 2

Important Considerations

The American Gastroenterological Association states that PPIs markedly reduce the likelihood of upper GI bleeding in patients on antithrombotic therapy, particularly in those with multiple risk factors for GI bleeding 2, 4
The European Society of Cardiology notes that long-term PPI use has been associated with potential adverse effects, including Clostridium difficile infection and pneumonia, and recommends regularly reassessing the need for continued PPI therapy 2, 5, 6

Special Situations

The American Gastroenterological Association recommends that patients with a history of peptic ulcer bleeding should definitely receive a PPI while on Eliquis, and that patients with Barrett's esophagus, severe erosive esophagitis, or idiopathic pulmonary fibrosis should generally continue PPI therapy regardless of anticoagulant use 2, 4, 6

Proton Pump Inhibitors in Gastrointestinal Bleeding Management

Appropriate Indications for PPI Use

The American Heart Association recommends PPIs for reducing upper GI bleeding risk in high-risk patients, such as those with a history of upper GI bleeding or those on antiplatelet therapy 7, 8
PPIs are indicated for prevention of GI bleeding in high-risk patients on antiplatelet therapy, according to the American College of Cardiology 7, 9, 10
The American Gastroenterological Association recommends PPIs for patients with a history of upper GI bleeding 8, 11
Patients with multiple risk factors for upper GI bleeding who require antiplatelet therapy may benefit from PPI therapy, as suggested by the American Heart Association 12, 13
Risk factors for upper GI bleeding that may warrant PPI therapy include prior GI bleeding history, advanced age, concurrent use of anticoagulants, steroids, or NSAIDs, Helicobacter pylori infection, and multiple antithrombotic agents, according to the American Gastroenterological Association 8, 11
The American Gastroenterological Association notes that unnecessary PPI therapy can lead to potential adverse effects, including risk of C. difficile infection, pneumonia, and nutrient malabsorption 8

Management of Patients on Eliquis with Prior GI Bleed

Risk Stratification and Indications for PPI Therapy

Patients with a history of upper GI bleeding who require anticoagulation represent the highest-risk category for recurrent bleeding events, warranting continued acid suppression 14
History of upper GI bleeding is the single strongest predictor of recurrence, justifying indefinite PPI use 14
The combination of prior GI bleeding and anticoagulant therapy places patients in the "definitely indicated for long-term use" category, according to the American Gastroenterological Association (AGA) guidelines 15

Evidence Supporting Indefinite PPI Therapy

The AGA Clinical Practice Update recommends that patients at high risk for upper GI bleeding, including those with a history of upper GI bleeding taking anticoagulants, should not be considered for PPI de-prescribing 14
The AGA guidelines identify patients with a history of upper GI bleeding taking anticoagulants as high-risk individuals who require ongoing PPI therapy 14

Optimal PPI Regimen

Once-daily standard-dose PPI is recommended, rather than twice-daily dosing, unless there is documented failure of standard dosing 15
The ongoing indication for PPI therapy should be clearly documented in the medical record, including the history of GI bleeding and current anticoagulation 15

Duration of Therapy

The indication for PPI therapy persists as long as the patient remains on Eliquis, according to the AGA guidelines 14
If anticoagulation is discontinued, reassessment for potential de-prescribing could occur, but this would require careful individualized risk-benefit analysis 14

Indications for PPI in DOAC Therapy

Risk-Based Approach to PPI Initiation

The European Society of Cardiology recommends proton pump inhibitors for patients on DOAC therapy who have increased risk of gastrointestinal bleeding, including those with prior GI bleeding, age >60 years, concurrent use of antiplatelet agents, NSAIDs, steroids, or multiple antithrombotic agents 16
Concurrent antiplatelet therapy (aspirin or P2Y12 inhibitors) is a strong indication for PPI therapy in patients on DOACs, as recommended by the European Heart Journal and Chest 16, 17

Specific Clinical Scenarios

A PPI is recommended for the entire duration of combined antithrombotic therapy when DOACs are used with antiplatelet agents, due to high bleeding risk, as indicated by the European Heart Journal and Chest 16, 17
PPI therapy is recommended when DOACs are combined with aspirin or clopidogrel, especially if additional risk factors are present, according to the European Heart Journal 16

Optimal PPI Regimen

Standard once-daily dosing of PPIs (e.g., omeprazole 20mg daily, pantoprazole 40mg daily) is appropriate for most patients, as suggested by Gastroenterology 18
Twice-daily dosing of PPIs should be reserved only for patients with complicated GERD, severe erosive esophagitis, or documented failure of once-daily therapy, as recommended by Gastroenterology 18

Important Considerations and Pitfalls

All patients on PPIs should have regular review of ongoing indications, with documentation of the specific reason for continued use, as advised by Gastroenterology 18
Patients at high risk for upper GI bleeding should not be considered for PPI discontinuation, according to Gastroenterology 18

Proton Pump Inhibitor Selection for Patients on Apixaban and Naproxen

Risk Assessment

The European Society of Cardiology recommends PPI therapy for patients receiving anticoagulants with concurrent NSAID use, as this combination dramatically increases bleeding risk 19
The American Heart Association identifies concurrent use of anticoagulants and NSAIDs as a definitive indication for PPI therapy 20
Concurrent anticoagulant use (apixaban) independently increases GI bleeding risk 19
NSAID use (naproxen) further compounds bleeding risk 20, 21
Combined antithrombotic therapy places the patient in the highest risk category for upper GI bleeding 19, 20

PPI Selection and Dosing

There is no clinically significant difference between individual PPIs when used with apixaban, unlike with clopidogrel where drug-drug interactions are a concern 20

Evidence Supporting PPI Efficacy

PPIs reduce both gastric and duodenal ulcers associated with NSAID use 21

Critical Clinical Considerations

Consider NSAID alternatives, as NSAIDs combined with anticoagulants carry substantial bleeding risk even with PPI therapy 20, 21
Screen for H. pylori, and eradication is recommended as an additional protective measure if the patient has any history of peptic ulcer disease 21
Do not withhold PPI therapy in this high-risk scenario, as the combination of anticoagulant plus NSAID is a definitive indication 19
Do not use H2-receptor antagonists instead, as PPIs are superior to H2RAs for preventing upper GI bleeding in patients on antithrombotic therapy 20, 21
Poor adherence to PPI therapy increases the risk of NSAID-induced upper GI adverse events 4-6 fold 21

Risks and Benefits of Proton Pump Inhibitor Use in Elderly Patients

Introduction to PPI Use in High-Risk Elderly Patients

The American Gastroenterological Association recommends that proton pump inhibitors should be continued indefinitely in elderly long-term care residents with impaired renal function and history of gastrointestinal bleeding, as the risk of recurrent life-threatening bleeding far outweighs the potential adverse effects of long-term PPI therapy 22

Risk-Benefit Analysis in High-Risk Elderly Patients

Patients with prior upper GI bleeding taking anticoagulants or antiplatelets represent the highest-risk category and should never be considered for PPI de-prescribing, according to the European Society of Cardiology 22, 23, 24
The combination of history of upper GI bleeding, advanced age (≥75 years), impaired renal function, and anticoagulant or antiplatelet therapy places patients in the "definitely indicated for long-term use" category where PPI therapy should continue as long as antithrombotic therapy is required, as stated by the European Heart Journal 22, 23, 24
Advanced age (≥75 years) increases bleeding risk, as reported by the European Heart Journal 23, 24
Impaired renal function increases anticoagulant exposure and bleeding risk, according to the European Heart Journal 24

Special Considerations for Renal Impairment

Renal impairment independently increases bleeding risk with anticoagulants, especially dabigatran and rivaroxaban, as noted by the European Heart Journal 24
This further strengthens the indication for PPI therapy as bleeding risk is compounded, according to the European Heart Journal 24
Monitor renal function periodically as both anticoagulants and PPIs may affect kidney function, as recommended by the European Heart Journal 24
Dose-adjust anticoagulants appropriately for renal function, as suggested by the European Heart Journal 24

Long-Term PPI Use in Patients Over 60 Years Old

Indications for Long-Term PPI Use

The American Gastroenterological Association recommends that patients over 65 years old who are taking NSAIDs and aspirin should continue PPI therapy, as the combination of NSAID and PPI is considered "appropriate" 25, 26
Patients over 65 years old with a history of GI complications and taking aspirin, warfarin, or steroids should continue PPI therapy 25, 26

Dosing Recommendations

The standard dose of pantoprazole is 40 mg once daily, which can be used for long-term therapy in patients with ongoing clinical indications 25, 26

Protonix and Eliquis Combination Therapy

Evidence Supporting Combined Use

The American Family Physician recommends considering PPI co-therapy with anticoagulants like Eliquis, especially in patients with concurrent NSAID use 27
The Journal of the American College of Cardiology states that there is no clinically significant interaction between PPIs and apixaban (Eliquis), making any PPI safe to use with Eliquis 28

Special Populations

Patients with prior GI bleeding should receive indefinite PPI therapy as long as they remain on Eliquis, as history of upper GI bleeding is the single strongest predictor of recurrence 27, 28

Proton Pump Inhibitor Use for Gastro‑intestinal Bleeding Prevention in Patients Receiving Antithrombotic Therapy

Indications Supported by Evidence

In patients receiving anticoagulant or antiplatelet agents, prophylactic use of a proton pump inhibitor reduces the risk of gastrointestinal bleeding. This recommendation is based on data reported in the European Heart Journal (2020) and reaffirmed in 2024. 29

Documentation Guidance from Professional Society

The European Society of Cardiology advises that, for individuals on dual antiplatelet therapy or anticoagulation, clinicians should explicitly record the bleeding‑risk factors that justify initiating a proton pump inhibitor, and code the therapy with Z79.899 as a secondary diagnosis. Evidence level was not specified in the cited guidelines. 30

Pantoprazole Use in Elderly Patients on Antithrombotic Therapy

Indications by Risk Level

High‑risk elderly (definite PPI indication): Patients aged ≥ 75 years who are receiving aspirin, NSAIDs, steroids, or warfarin should receive pantoprazole 40 mg once daily indefinitely to prevent upper‑GI bleeding. 31
Moderate‑risk elderly (consider PPI): Patients aged ≥ 65 years who are on aspirin alone merit a trial of pantoprazole 40 mg once daily for gastroprotection. 32
Low‑risk elderly (PPI generally not indicated): Patients younger than 65 years without aspirin use, prior GI events, or NSAID exposure do not require routine pantoprazole therapy. 32

Drug‑Interaction Profile

Pantoprazole exhibits the lowest potential for clinically relevant drug‑drug interactions among proton‑pump inhibitors, making it suitable for elderly patients with polypharmacy. It does not significantly inhibit CYP2C19 and is compatible with commonly prescribed cardiovascular medications. 31

Dosing Considerations

A standard dose of pantoprazole 40 mg once daily is appropriate for most elderly patients; no dose reduction is required solely on the basis of age. 33
Dose escalation to twice daily should be reserved for documented failure of once‑daily therapy.

Gastro‑Protection with NSAIDs

In elderly patients aged ≥ 75 years who use NSAIDs and have any of the following risk factors—peptic ulcer disease, prior GI bleeding, concurrent anticoagulant/antiplatelet/SSRI/glucocorticoid therapy—a concomitant pantoprazole regimen is recommended to prevent upper‑GI bleeding. 31

Monitoring and Safety

Long‑term pantoprazole therapy should be reviewed periodically, but continuation is advised while antithrombotic therapy persists, especially after a history of GI bleeding.
Clinicians should monitor for potential adverse effects of prolonged PPI use, including Clostridioides difficile infection, hypomagnesemia, and decreased bone density or fractures after more than 12 weeks of therapy. 33

Cardiovascular Considerations

Elderly patients with cardiovascular disease benefit from pantoprazole’s lack of interaction with cardiovascular drugs and its preservation of antiplatelet efficacy when combined with agents such as clopidogrel. 31

PPI Indications and Safety Considerations for Elderly Patients

Indications for Proton Pump Inhibitor Therapy

Elderly patients (age ≥ 65 years) who are prescribed non‑steroidal anti‑inflammatory drugs (with or without aspirin) should receive a proton pump inhibitor to lower the risk of upper gastrointestinal toxicity.  [Expert consensus – strong recommendation] 34
The appropriateness rating for adding a PPI in patients aged ≥ 65 years is increased by four points compared with younger patients, indicating a markedly higher level of consensus for use in this age group. [Expert consensus – moderate‑to‑strong recommendation] 35, 36
For patients aged 65–74 years who are using NSAIDs, a standard dose of pantoprazole 40 mg once daily is required to mitigate bleeding risk. [Expert consensus – strong recommendation] 34
In individuals younger than 65 years without gastrointestinal risk factors, routine prophylactic PPI therapy is not recommended unless a specific clinical indication exists. [Expert consensus – weak recommendation] 34

Dosing Recommendations for Elderly Patients

Pantoprazole 40 mg taken once daily is the preferred regimen for elderly patients; no age‑based dose reduction is needed. [Expert consensus – strong recommendation] 34

Long‑Term Safety Risks of Chronic PPI Use

Prolonged PPI therapy in older adults is associated with an increased risk of Clostridium difficile infection. [Observational data – moderate evidence] 37

Proton‑Pump Inhibitor Prescribing & Deprescribing in Elderly Patients

1. Indication Documentation & Review

All patients aged ≥ 65 years on a PPI must have a documented indication that is reviewed regularly by the primary‑care clinician; those without a definitive long‑term indication should be considered for deprescribing, whereas patients with high‑risk features (e.g., prior gastrointestinal bleeding, concurrent anticoagulant/antiplatelet therapy, or severe erosive esophagitis) should continue therapy indefinitely. [38][39]

2. Definitive Long‑Term Indications (continue PPI indefinitely)

Barrett’s esophagus warrants indefinite PPI therapy. [38][39]
Severe erosive esophagitis (Los Angeles grade C/D) warrants indefinite PPI therapy. [38][39]
A history of esophageal ulcer or peptic stricture warrants indefinite PPI therapy. [38][39]
Zollinger‑Ellison syndrome warrants indefinite PPI therapy. [38][39]

3. Dosing Strategies

Standard once‑daily dosing is appropriate for most elderly patients; twice‑daily dosing should be reserved only for documented failure of once‑daily therapy or for complicated GERD with severe erosive esophagitis. [38][39]
Double‑dose (standard dose twice daily) PPIs are not FDA‑approved and are associated with higher risks of community‑acquired pneumonia, hip fracture, and Clostridium difficile infection without proven additional benefit. [38][39]

4. Duration of Therapy

Short‑Term Indications (≤ 8 weeks)

Uncomplicated GERD or dyspepsia: a 4‑ to 8‑week trial is recommended. [38][39]
Helicobacter pylori eradication regimens: 14 days of PPI therapy. [38][39]
Acute peptic ulcer disease: 4‑ to 8‑week course. [38][39]

Long‑Term Therapy (> 8 weeks)

Indefinite continuation is justified only for the definitive indications listed above. [38][39]
For patients with PPI‑responsive, endoscopy‑negative reflux disease who relapse after stopping therapy, long‑term PPI use is conditionally indicated. [38][39]

5. Documentation Requirements at Each Visit

Record the specific ongoing indication for PPI use. [38][39]
Assess whether the indication remains valid. [38][39]
Consider deprescribing if no definitive long‑term indication exists. [38][39]

6. Deprescribing Candidates & Contra‑indications

Candidates for deprescribing include patients with non‑erosive reflux disease lacking sustained response and those started on a PPI for an unclear or undocumented indication. [38][39]
Deprescribing should not be performed in patients with a history of severe erosive esophagitis, esophageal ulcer, peptic stricture, or Barrett’s esophagus. [38][39]

7. Deprescribing Algorithm (Gradual Taper)

8. Common Pitfalls & Recommended Practices

Avoid continuing a PPI indefinitely without a documented indication. [38][39]
Avoid using twice‑daily dosing without documented failure of once‑daily therapy. [38][39]
Avoid empiric PPI prescription for laryngopharyngeal symptoms without documented reflux. [38][39]
Do document the specific indication at every patient encounter. [38][39]
Do use standard once‑daily dosing as the first‑line regimen. [38][39]

9. Evidence on Adverse Events

Randomized controlled trials have not demonstrated higher rates of adverse events (e.g., pneumonia, fractures, C. difficile infection) with PPIs compared with placebo; the observed associations in observational studies underscore the importance of confirming a valid ongoing indication before long‑term use. [38][39]

Management of Gastric Angiodysplasia and the Role of Proton‑Pump Inhibitors

Pathophysiology

Gastric angiodysplasias develop through hypoxia‑induced angiogenesis, a process unrelated to gastric acid exposure. 40

Situations in Which PPIs Are Indicated

High‑Risk Bleeding Prevention

In patients with gastric angiodysplasia who have a history of prior upper‑GI bleeding, PPIs should be prescribed to protect against bleeding from coexisting acid‑related lesions. 41
Concurrent dual antiplatelet therapy (e.g., aspirin + clopidogrel) constitutes an additional bleeding risk that justifies PPI use. 42

Post‑Endoscopic Therapy

After endoscopic thermal ablation of bleeding angiodysplasia, high‑dose intravenous PPI therapy (80 mg bolus followed by 8 mg/h continuous infusion for 72 h) is recommended to prevent rebleeding from the iatrogenic ulcer created by the procedure. 40

Long‑Term PPI Use for Coexisting Acid‑Related Disease

PPIs reduce rebleeding risk only when they address a separate acid‑related pathology (e.g., peptic ulcer disease) or when they stabilize post‑procedure ulcers; they do not affect the intrinsic bleeding tendency of angiodysplastic vessels. 41
Patients with documented angiodysplasia‑related bleeding who are also on anticoagulants or antiplatelet agents have a definitive indication for indefinite PPI therapy to protect against ulcer‑related bleeding. 40